Amer A Alkhatib1, Kristen Hilden, Douglas G Adler. 1. Gastroenterology and Hepatology, Huntsman Cancer Center, University of Utah School of Medicine, 30N 1900E 4R118, Salt Lake City, UT 84132, USA.
Abstract
BACKGROUND: Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease. Interventional ERCP improves survival in PSC patients. AIMS: To describe the frequency and risk factors for post-ERCP adverse events in patients with PSC via multivariate analysis. METHODS: Retrospective cohort study included patients with a diagnosis of PSC who underwent ERCP at academic institutions between February 2000 and October 2009. Demographis, co-morbid conditions, antibiotic use, cannulation method, ERCP maneuvers and 30-day post-ERCP adverse events were collected. Multivariate analysis was performed using logistic regression. RESULTS: A total of 185 procedures were performed on 75 PSC patients (58 M,17 F). Seven endoscopists performed ERCPs. Comorbidies included ulcerative colitis (44%, n = 33), Crohn's disease (12%, n = 9 patients), Cirrhosis (8%, n = 6 patients) and autoimmune hepatitis (2.7%, n = 2). Cannulation was achieved using dye-free guidewire cannulation techniques in 139/185 procedures (76%) and with contrast-based techniques in 46/185 procedures (24%). Thirty-day post-ERCP adverse events included post-ERCP pancreatitis (5%, n = 9, cholangitis (1%, n = 2), acute cholecystitis (0.5%, n = 1), stent occlusion (0.5%, n = 1), stent migration (0.5%, n = 1), and bile leak (0.5%, n = 1). In the multivariate analysis, associations with specific endoscopists who performed the procedure (P = 0.01), biliary dilation (P = 0.02), sphincterotomy (P = 0.03), presence of cirrhosis (P = 0.05), Crohn's disease (P < 0.001), and autoimmune hepatitis (P < 0.001) significantly predicted a complication following ERCP. Gender, stenting during procedure, presence of a dominant stricture, and cholangitis were not predictive for post-ERCP adverse events. CONCLUSIONS: Factors predicting 30-day post-ERCP adverse events included certain co-morbid conditions, the endoscopist ERCP volume, maneuvers during ERCP including dilation and sphincterotomy. Stenting was not associated with adverse events.
BACKGROUND:Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease. Interventional ERCP improves survival in PSC patients. AIMS: To describe the frequency and risk factors for post-ERCP adverse events in patients with PSC via multivariate analysis. METHODS: Retrospective cohort study included patients with a diagnosis of PSC who underwent ERCP at academic institutions between February 2000 and October 2009. Demographis, co-morbid conditions, antibiotic use, cannulation method, ERCP maneuvers and 30-day post-ERCP adverse events were collected. Multivariate analysis was performed using logistic regression. RESULTS: A total of 185 procedures were performed on 75 PSC patients (58 M,17 F). Seven endoscopists performed ERCPs. Comorbidies included ulcerative colitis (44%, n = 33), Crohn's disease (12%, n = 9 patients), Cirrhosis (8%, n = 6 patients) and autoimmune hepatitis (2.7%, n = 2). Cannulation was achieved using dye-free guidewire cannulation techniques in 139/185 procedures (76%) and with contrast-based techniques in 46/185 procedures (24%). Thirty-day post-ERCP adverse events included post-ERCP pancreatitis (5%, n = 9, cholangitis (1%, n = 2), acute cholecystitis (0.5%, n = 1), stent occlusion (0.5%, n = 1), stent migration (0.5%, n = 1), and bile leak (0.5%, n = 1). In the multivariate analysis, associations with specific endoscopists who performed the procedure (P = 0.01), biliary dilation (P = 0.02), sphincterotomy (P = 0.03), presence of cirrhosis (P = 0.05), Crohn's disease (P < 0.001), and autoimmune hepatitis (P < 0.001) significantly predicted a complication following ERCP. Gender, stenting during procedure, presence of a dominant stricture, and cholangitis were not predictive for post-ERCP adverse events. CONCLUSIONS: Factors predicting 30-day post-ERCP adverse events included certain co-morbid conditions, the endoscopist ERCP volume, maneuvers during ERCP including dilation and sphincterotomy. Stenting was not associated with adverse events.
Authors: Matthew L Silviera; Mark J Seamon; Brian Porshinsky; Mark P Prosciak; Vijay A Doraiswamy; Cecilia F Wang; Manuel Lorenzo; Michael Truitt; John Biboa; Amy M Jarvis; Vimal K Narula; Steven M Steinberg; S Peter Stawicki Journal: J Gastrointestin Liver Dis Date: 2009-03 Impact factor: 2.008
Authors: M Kaya; B T Petersen; P Angulo; T H Baron; J C Andrews; C J Gostout; K D Lindor Journal: Am J Gastroenterol Date: 2001-04 Impact factor: 10.864
Authors: M L Freeman; J A DiSario; D B Nelson; M B Fennerty; J G Lee; D J Bjorkman; C S Overby; J Aas; M E Ryan; G S Bochna; M J Shaw; H W Snady; R V Erickson; J P Moore; J P Roel Journal: Gastrointest Endosc Date: 2001-10 Impact factor: 9.427
Authors: Jason P Etzel; Sue C Eng; Cynthia W Ko; Scott D Lee; Michael D Saunders; Bruce Y Tung; Michael B Kimmey; Kris V Kowdley Journal: Gastrointest Endosc Date: 2007-12-03 Impact factor: 9.427
Authors: Jo Vandervoort; Roy M Soetikno; Tony C K Tham; Richard C K Wong; Angelo P Ferrari; Henry Montes; Alfred D Roston; Adam Slivka; David R Lichtenstein; Frederick W Ruymann; Jacques Van Dam; Mike Hughes; David L Carr-Locke Journal: Gastrointest Endosc Date: 2002-11 Impact factor: 9.427
Authors: Sanjay Y Bangarulingam; Andrea A Gossard; Bret T Petersen; Beverly J Ott; Keith D Lindor Journal: Am J Gastroenterol Date: 2009-03-03 Impact factor: 10.864
Authors: Douglas G Adler; John G Lieb; Jonathan Cohen; Irving M Pike; Walter G Park; Maged K Rizk; Mandeep S Sawhney; James M Scheiman; Nicholas J Shaheen; Stuart Sherman; Sachin Wani Journal: Am J Gastroenterol Date: 2014-12-02 Impact factor: 10.864
Authors: John E Eaton; Jayant A Talwalkar; Konstantinos N Lazaridis; Gregory J Gores; Keith D Lindor Journal: Gastroenterology Date: 2013-07-01 Impact factor: 22.682